These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 1171221

  • 1. Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
    Schapel GJ, Edwards KD.
    J Pharmacol Exp Ther; 1975 Jul; 194(1):274-84. PubMed ID: 1171221
    [Abstract] [Full Text] [Related]

  • 2. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
    Krut LH, Seftel HC, Joffe BI.
    S Afr Med J; 1977 Mar 12; 51(11):348-52. PubMed ID: 323994
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
    Keller C, Wolfram G, Zöllner N.
    Arzneimittelforschung; 1976 Mar 12; 26(12):2221-4. PubMed ID: 798591
    [Abstract] [Full Text] [Related]

  • 4. One-year trials with halofenate, clofibrate, and placebo.
    Dujovne CA, Azarnoff DL, Huffman DH, Pentikäinen P, Hurwitz A, Shoeman DW.
    Clin Pharmacol Ther; 1976 Mar 12; 19(3):352-9. PubMed ID: 177242
    [Abstract] [Full Text] [Related]

  • 5. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
    Rees ED, Hamilton RD, Kanner IF, Wasson S, Hearn T.
    Atherosclerosis; 1976 Sep 12; 24(3):537-46. PubMed ID: 788722
    [Abstract] [Full Text] [Related]

  • 6. A two-year crossover therapeutic trial with halofenate and clofibrate.
    Dujovne CA, Azarnoff DL, Pentikainen P, Manion C, Hurwitz A, Hassanein K.
    Am J Med Sci; 1976 Sep 12; 272(3):277-84. PubMed ID: 797258
    [Abstract] [Full Text] [Related]

  • 7. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
    Neuman J, de Neuman MP, Talmasky S, Pesce R, Valero E, Martiarena JL.
    J Cardiovasc Surg (Torino); 1973 Sep 12; Spec No():532-7. PubMed ID: 4377715
    [No Abstract] [Full Text] [Related]

  • 8. Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.
    Cenedella RJ, Crouthamel WG.
    J Lipid Res; 1976 Mar 12; 17(2):156-66. PubMed ID: 1270931
    [Abstract] [Full Text] [Related]

  • 9. A one year double blind study of the effect of halofenate and clofibrate in patients with hyperlipoproteinemia.
    Rottiers R, van Egmond J.
    Acta Clin Belg; 1975 Mar 12; 30(5):398-408. PubMed ID: 1221746
    [No Abstract] [Full Text] [Related]

  • 10. Potentiation of hypoglycemic effect of sulfonylureas by halofenate.
    Jain AK, Ryan JR, McMahon FG.
    N Engl J Med; 1975 Dec 18; 293(25):1283-6. PubMed ID: 171574
    [Abstract] [Full Text] [Related]

  • 11. Factorial study of the efficacy of cholestyramine, L-tryptophan and clofibrate in human nephrotic hyperlipidaemia.
    Schapel GJ, Edwards KD, Neale FC.
    Prog Biochem Pharmacol; 1974 Dec 18; 9():82-98. PubMed ID: 4438384
    [No Abstract] [Full Text] [Related]

  • 12. Halofenate: a potent inhibitor of normal and hypersensitive platelets.
    Colman RW, Bennett JS, Sheridan JF, Cooper RA, Shattil SJ.
    J Lab Clin Med; 1976 Aug 18; 88(2):282-91. PubMed ID: 956686
    [Abstract] [Full Text] [Related]

  • 13. The metabolic spectrum of halofenate.
    Ryan JR.
    Int J Clin Pharmacol Biopharm; 1975 Jul 18; 12(1-2):239-43. PubMed ID: 51838
    [Abstract] [Full Text] [Related]

  • 14. Effects of S-methylmethionine (vitamin U) on experimental nephrotic hyperlipidemia.
    Seri K, Amemiya K, Sugimoto H, Kato T.
    Arzneimittelforschung; 1979 Jul 18; 29(10):1517-20. PubMed ID: 583214
    [Abstract] [Full Text] [Related]

  • 15. [First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
    Wolfram G, Keller C, Kilani C, Zöllner N.
    Verh Dtsch Ges Inn Med; 1973 Jul 18; 79():1291-3. PubMed ID: 4597609
    [No Abstract] [Full Text] [Related]

  • 16. [Lipid depression by etofibrate in a comparative study in rats with artificial hyperlipidemia].
    Sterner W, Schultz A.
    Arzneimittelforschung; 1974 Dec 18; 24(12):1990-2. PubMed ID: 4480360
    [No Abstract] [Full Text] [Related]

  • 17. Clofibrate treatment of hyperlipidemia in chronic renal failure.
    di Giulio S, Boulu R, Drüeke T, Nicolaĭ A, Zingraff J, Crosnier J.
    Clin Nephrol; 1977 Dec 18; 8(6):504-9. PubMed ID: 598055
    [Abstract] [Full Text] [Related]

  • 18. Hypolipidemic drugs.
    Sirtori C, Fumagalli R, Paoletti R.
    Adv Exp Med Biol; 1973 Dec 18; 38():171-98. PubMed ID: 4594063
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
    Lisch HJ, Patsch J, Sailer S, Braunsteiner H.
    Atherosclerosis; 1975 Dec 18; 21(3):391-9. PubMed ID: 1148032
    [Abstract] [Full Text] [Related]

  • 20. High density lipoproteins during hypolipidemic therapy. A comparative study of four drugs.
    Cheung MC, Albers JJ, Wahl PW, Hazzard WR.
    Atherosclerosis; 1980 Mar 18; 35(3):215-28. PubMed ID: 7362696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.